Private Advisor Group LLC Has $6.37 Million Holdings in Stryker Corporation (NYSE:SYK)

Private Advisor Group LLC lifted its position in Stryker Corporation (NYSE:SYK - Free Report) by 6.7% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 17,100 shares of the medical technology company's stock after purchasing an additional 1,073 shares during the quarter. Private Advisor Group LLC's holdings in Stryker were worth $6,366,000 at the end of the most recent reporting period.

Other large investors have also modified their holdings of the company. Elefante Mark B purchased a new stake in shares of Stryker during the 4th quarter worth $337,000. Mogy Joel R Investment Counsel Inc. increased its stake in Stryker by 3.4% during the 1st quarter. Mogy Joel R Investment Counsel Inc. now owns 98,216 shares of the medical technology company's stock worth $36,561,000 after buying an additional 3,218 shares during the period. Ferguson Wellman Capital Management Inc. boosted its stake in Stryker by 1.9% during the 1st quarter. Ferguson Wellman Capital Management Inc. now owns 174,871 shares of the medical technology company's stock valued at $65,096,000 after purchasing an additional 3,341 shares during the period. Harbor Capital Advisors Inc. acquired a new stake in shares of Stryker during the first quarter valued at approximately $1,840,000. Finally, Mar Vista Investment Partners LLC grew its position in Stryker by 10.2% in the first quarter. Mar Vista Investment Partners LLC now owns 90,187 shares of the medical technology company's stock worth $33,572,000 after acquiring an additional 8,353 shares in the last quarter. Hedge funds and other institutional investors own 77.09% of the company's stock.

Stryker Stock Performance

NYSE:SYK traded down $1.82 during mid-day trading on Monday, reaching $387.58. The company's stock had a trading volume of 791,681 shares, compared to its average volume of 1,349,256. The firm's fifty day moving average price is $385.67 and its two-hundred day moving average price is $378.19. The stock has a market cap of $147.94 billion, a P/E ratio of 31.08, a PEG ratio of 2.94 and a beta of 0.91. Stryker Corporation has a 12-month low of $314.93 and a 12-month high of $406.19. The company has a current ratio of 1.64, a quick ratio of 1.00 and a debt-to-equity ratio of 0.69.

Stryker (NYSE:SYK - Get Free Report) last announced its quarterly earnings results on Thursday, May 1st. The medical technology company reported $2.84 EPS for the quarter, beating the consensus estimate of $2.73 by $0.11. The firm had revenue of $5.87 billion for the quarter, compared to analyst estimates of $5.68 billion. Stryker had a return on equity of 23.74% and a net margin of 12.31%. The business's revenue for the quarter was up 11.9% on a year-over-year basis. During the same quarter last year, the firm posted $2.50 earnings per share. On average, equities analysts forecast that Stryker Corporation will post 13.47 EPS for the current fiscal year.

Stryker Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Thursday, July 31st. Investors of record on Monday, June 30th will be paid a $0.84 dividend. The ex-dividend date is Monday, June 30th. This represents a $3.36 dividend on an annualized basis and a dividend yield of 0.87%. Stryker's dividend payout ratio (DPR) is presently 45.41%.

Wall Street Analyst Weigh In

SYK has been the subject of several research analyst reports. Wall Street Zen raised Stryker from a "hold" rating to a "buy" rating in a research report on Friday. Evercore ISI raised their price objective on Stryker from $390.00 to $415.00 and gave the company an "outperform" rating in a research note on Tuesday, July 8th. Roth Mkm upped their target price on Stryker from $405.00 to $456.00 and gave the company a "buy" rating in a research report on Friday, May 2nd. BTIG Research reaffirmed a "buy" rating on shares of Stryker in a report on Monday, July 14th. Finally, Citigroup reiterated a "buy" rating and issued a $455.00 price objective (up from $443.00) on shares of Stryker in a research report on Thursday, May 22nd. Four investment analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the company. Based on data from MarketBeat.com, Stryker currently has an average rating of "Moderate Buy" and a consensus price target of $428.55.

Insider Transactions at Stryker

In other news, Director Ronda E. Stryker sold 200,000 shares of the company's stock in a transaction dated Tuesday, May 6th. The stock was sold at an average price of $376.96, for a total value of $75,392,000.00. Following the completion of the sale, the director owned 3,417,326 shares of the company's stock, valued at $1,288,195,208.96. This represents a 5.53% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Corporate insiders own 5.20% of the company's stock.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.